Becton, Dickinson and Company (NYSE:BDX) Releases FY 2026 Earnings Guidance

Becton, Dickinson and Company (NYSE:BDX) issued an update on its FY 2026 earnings guidance on Thursday. The company provided earnings per share guidance of 12.620-12.720 for the period, compared to the consensus earnings per share estimate of 12.560. The company issued revenue guidance of -.

Becton, Dickinson and Company Trading Up 0.1%

BDX opened at $170.30 on Thursday. The company’s 50 day moving average price is $153.20 and its two-hundred day moving average price is $162.62. The firm has a market capitalization of $46.93 billion, a price-to-earnings ratio of 43.11, a PEG ratio of 12.12 and a beta of 0.19. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $187.35. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.94 and a quick ratio of 0.55.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, beating analysts’ consensus estimates of $3.14 by $0.09. The business had revenue of $4.98 billion during the quarter, compared to the consensus estimate of $4.89 billion. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, research analysts predict that Becton, Dickinson and Company will post 12.53 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be issued a $1.05 dividend. The ex-dividend date is Wednesday, September 9th. This represents a $4.20 annualized dividend and a yield of 2.5%. Becton, Dickinson and Company’s dividend payout ratio is presently 106.33%.

Analysts Set New Price Targets

BDX has been the subject of a number of recent analyst reports. Weiss Ratings downgraded shares of Becton, Dickinson and Company from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, May 11th. UBS Group initiated coverage on shares of Becton, Dickinson and Company in a research note on Tuesday, July 28th. They issued a “buy” rating and a $190.00 price objective on the stock. The Goldman Sachs Group decreased their price objective on shares of Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating for the company in a research report on Wednesday, May 27th. Royal Bank Of Canada set a $175.00 target price on shares of Becton, Dickinson and Company in a report on Tuesday, April 14th. Finally, Barclays upped their price target on shares of Becton, Dickinson and Company from $202.00 to $204.00 and gave the company an “overweight” rating in a research report on Monday, May 11th. Eight equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Becton, Dickinson and Company presently has an average rating of “Hold” and an average price target of $182.20.

Insider Activity

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,100 shares of the stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total transaction of $160,226.00. Following the completion of the transaction, the executive vice president owned 13,172 shares in the company, valued at $1,918,633.52. This trade represents a 7.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 2,764 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $146.35, for a total value of $404,511.40. Following the completion of the transaction, the chief executive officer owned 110,163 shares of the company’s stock, valued at approximately $16,122,355.05. This represents a 2.45% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 5,189 shares of company stock valued at $765,661. 0.40% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Becton, Dickinson and Company

A number of hedge funds have recently made changes to their positions in BDX. Imprint Wealth LLC purchased a new stake in Becton, Dickinson and Company during the third quarter valued at about $25,000. Prosperity Bancshares Inc bought a new position in shares of Becton, Dickinson and Company in the fourth quarter worth approximately $29,000. Johnson Financial Group Inc. bought a new stake in shares of Becton, Dickinson and Company in the third quarter worth about $33,000. Kelleher Financial Advisors purchased a new stake in Becton, Dickinson and Company in the 3rd quarter worth approximately $37,000. Finally, Miller Capital Partners Inc. purchased a new position in shares of Becton, Dickinson and Company during the fourth quarter valued at approximately $43,000. 86.97% of the stock is currently owned by institutional investors.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.